651 related articles for article (PubMed ID: 26220395)
21. Different recognition modes of G-quadruplex RNA between two ALS/FTLD-linked proteins TDP-43 and FUS.
Ishiguro A; Katayama A; Ishihama A
FEBS Lett; 2021 Feb; 595(3):310-323. PubMed ID: 33269497
[TBL] [Abstract][Full Text] [Related]
22. Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations.
Neumann M; Valori CF; Ansorge O; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ishihara K; Ang LC; Bilbao JM; Mackenzie IR
Acta Neuropathol; 2012 Nov; 124(5):705-16. PubMed ID: 22842875
[TBL] [Abstract][Full Text] [Related]
23. Nuclear carrier and RNA-binding proteins in frontotemporal lobar degeneration associated with fused in sarcoma (FUS) pathological changes.
Davidson YS; Robinson AC; Hu Q; Mishra M; Baborie A; Jaros E; Perry RH; Cairns NJ; Richardson A; Gerhard A; Neary D; Snowden JS; Bigio EH; Mann DM
Neuropathol Appl Neurobiol; 2013 Feb; 39(2):157-65. PubMed ID: 22497712
[TBL] [Abstract][Full Text] [Related]
24. Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS.
Ito D; Suzuki N
Neurology; 2011 Oct; 77(17):1636-43. PubMed ID: 21956718
[TBL] [Abstract][Full Text] [Related]
25. Heterogeneous nuclear ribonucleoproteins R and Q accumulate in pathological inclusions in FTLD-FUS.
Gittings LM; Foti SC; Benson BC; Gami-Patel P; Isaacs AM; Lashley T
Acta Neuropathol Commun; 2019 Feb; 7(1):18. PubMed ID: 30755280
[TBL] [Abstract][Full Text] [Related]
26. [The molecular pathology of frontotemporal lobar degeneration].
Fujishiro H; Hasegawa M; Arai T
Seishin Shinkeigaku Zasshi; 2010; 112(4):313-24. PubMed ID: 20496755
[TBL] [Abstract][Full Text] [Related]
27. Atypical FTLD-FUS associated with ALS-TDP: a case report.
Kobayashi Z; Arai T; Yokota O; Tsuchiya K; Hosokawa M; Oshima K; Niizato K; Akiyama H; Mizusawa H
Neuropathology; 2013 Feb; 33(1):83-6. PubMed ID: 22640227
[TBL] [Abstract][Full Text] [Related]
28. Frontotemporal lobar degeneration: diversity of FTLD lesions.
Seilhean D; Bielle F; Plu I; Duyckaerts C
Rev Neurol (Paris); 2013 Oct; 169(10):786-92. PubMed ID: 24035575
[TBL] [Abstract][Full Text] [Related]
29. Frontotemporal lobar degeneration: Pathogenesis, pathology and pathways to phenotype.
Mann DMA; Snowden JS
Brain Pathol; 2017 Nov; 27(6):723-736. PubMed ID: 28100023
[TBL] [Abstract][Full Text] [Related]
30. Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs.
Lagier-Tourenne C; Polymenidou M; Hutt KR; Vu AQ; Baughn M; Huelga SC; Clutario KM; Ling SC; Liang TY; Mazur C; Wancewicz E; Kim AS; Watt A; Freier S; Hicks GG; Donohue JP; Shiue L; Bennett CF; Ravits J; Cleveland DW; Yeo GW
Nat Neurosci; 2012 Nov; 15(11):1488-97. PubMed ID: 23023293
[TBL] [Abstract][Full Text] [Related]
31. Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease.
Luty AA; Kwok JB; Dobson-Stone C; Loy CT; Coupland KG; Karlström H; Sobow T; Tchorzewska J; Maruszak A; Barcikowska M; Panegyres PK; Zekanowski C; Brooks WS; Williams KL; Blair IP; Mather KA; Sachdev PS; Halliday GM; Schofield PR
Ann Neurol; 2010 Nov; 68(5):639-49. PubMed ID: 21031579
[TBL] [Abstract][Full Text] [Related]
32. Understanding the role of TDP-43 and FUS/TLS in ALS and beyond.
Da Cruz S; Cleveland DW
Curr Opin Neurobiol; 2011 Dec; 21(6):904-19. PubMed ID: 21813273
[TBL] [Abstract][Full Text] [Related]
33. Implications of the prion-related Q/N domains in TDP-43 and FUS.
Udan M; Baloh RH
Prion; 2011; 5(1):1-5. PubMed ID: 21135580
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms Associated with TDP-43 Neurotoxicity in ALS/FTLD.
Shenouda M; Zhang AB; Weichert A; Robertson J
Adv Neurobiol; 2018; 20():239-263. PubMed ID: 29916022
[TBL] [Abstract][Full Text] [Related]
35. Inclusions in frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP) and amyotrophic lateral sclerosis (ALS), but not FTLD with FUS proteinopathy (FTLD-FUS), have properties of amyloid.
Bigio EH; Wu JY; Deng HX; Bit-Ivan EN; Mao Q; Ganti R; Peterson M; Siddique N; Geula C; Siddique T; Mesulam M
Acta Neuropathol; 2013 Mar; 125(3):463-5. PubMed ID: 23378033
[No Abstract] [Full Text] [Related]
36. FUS mutations in frontotemporal lobar degeneration with amyotrophic lateral sclerosis.
Broustal O; Camuzat A; Guillot-Noël L; Guy N; Millecamps S; Deffond D; Lacomblez L; Golfier V; Hannequin D; Salachas F; Camu W; Didic M; Dubois B; Meininger V; Le Ber I; Brice A;
J Alzheimers Dis; 2010; 22(3):765-9. PubMed ID: 21158017
[TBL] [Abstract][Full Text] [Related]
37. Targeting RACK1 to alleviate TDP-43 and FUS proteinopathy-mediated suppression of protein translation and neurodegeneration.
Zhao B; Cowan CM; Coutts JA; Christy DD; Saraph A; Hsueh SCC; Plotkin SS; Mackenzie IR; Kaplan JM; Cashman NR
Acta Neuropathol Commun; 2023 Dec; 11(1):200. PubMed ID: 38111057
[TBL] [Abstract][Full Text] [Related]
38. Fused in sarcoma (FUS): an oncogene goes awry in neurodegeneration.
Dormann D; Haass C
Mol Cell Neurosci; 2013 Sep; 56():475-86. PubMed ID: 23557964
[TBL] [Abstract][Full Text] [Related]
39. FET proteins in frontotemporal dementia and amyotrophic lateral sclerosis.
Mackenzie IR; Neumann M
Brain Res; 2012 Jun; 1462():40-3. PubMed ID: 22261247
[TBL] [Abstract][Full Text] [Related]
40. The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene.
Snowden JS; Hu Q; Rollinson S; Halliwell N; Robinson A; Davidson YS; Momeni P; Baborie A; Griffiths TD; Jaros E; Perry RH; Richardson A; Pickering-Brown SM; Neary D; Mann DM
Acta Neuropathol; 2011 Jul; 122(1):99-110. PubMed ID: 21424531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
